Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates.

ABSTRACT:

Background

Olanzapine, regarded as one of the most efficacious antipsychotic medications for the treatment of schizophrenia, is associated with a high risk of weight gain and metabolic dysfunction. ALKS 3831, a clinical candidate for treatment of schizophrenia, is a combination of olanzapine and samidorphan, an opioid receptor antagonist. The addition of samidorphan is intended to mitigate weight gain and the metabolic dysregulation associated with the use of olanzapine.

Methods

Non-clinical studies were conducted to assess the metabolic effects of olanzapine and samidorphan alone and in combination at clinically relevant exposure levels.

Results

Chronic olanzapine administration in male and female rats shifted body composition by increasing adipose mass, which was ac

SUBMITTER: Cunningham JI 

PROVIDER: S-EPMC6764014 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature